State Bank of India has finalised a $1 billion tranche inside the syndicate financing Sun Pharmaceutical Industries’ $11.75 billion all-cash acquisition of Organon & Co., alongside Citigroup, JPMorgan, and MUFG. The deal itself is a genuine milestone with an Indian pharmaceutical major moving into the global top 25 on the back of a leveraged outbound tender offer. The more useful detail for anyone advising cross-border structures is the regulatory mechanism that made SBI’s participation possible at all: a recent RBI liberalisation permitting state-run banks into high-leverage outbound acquisition financing that was, until recently, functionally reserved for tier-one international lenders.
Read on its own, this looks like a straightforward story about India’s largest public-sector bank stepping up to Wall Street’s table. Read alongside the rest of the current regulatory picture, it is one half of a policy the state is running on two tracks at once.
Track I: The Liberalisation
Institutional, transparent, top-tier borrowers are being cleared to move faster and access larger, better-syndicated pools of outbound capital than before. The macro-economic pressure driving this is clear: traditional Indian generics are facing steep price erosion in mature western markets, highlighted by an acute 23.2% year-on-year drop in generic exports. To escape the plain-vanilla margin squeeze, corporate leaders are using liberalised outbound pipelines to buy high-barrier assets like Organon’s top-10 global biosimilar footprint. This strategic push is what drove India’s second-quarter M&A activity to a four-year high, capturing 565 transactions worth a staggering $36.3 billion.
Track II: Compliances
While top-tier multinationals deploy cross-border syndicates, domestic tax and regulatory desks are executing intensive, backward-looking audits. The kind of structures that don’t fit the institutionally transparency description are being examined closely: The Income Tax Department has dispatched an unprecedented wave of Section 148 notices, aggressively reopening legacy offshore fund and FPI books for retrospective audit even where structures did not actively repatriate direct dividend or profit income. Symmetrically, the RBI is breaking up digital monopolies by forcing strict interoperability protocols across the Trade Receivables Discounting System (TReDS) ecosystem to dismantle closed-loop trade financing networks.
Neither track is a reaction to the other. They are the same regulator drawing a sharper line between capital that is prepared to be examined and capital that has historically preferred not to be examined.
Upcoming Internal Reviews
The interesting question this raises is not about SBI or Sun Pharma, both of whom sit comfortably on the cleared side of that line. It is about the much larger population of cross-border holding structures that do not, for example family offices, mid-market multinationals, private equity vehicles with legacy multi-tier offshore layers built up across separate common-law seats over the past decade. Many of these structures were built under an earlier regulatory environment, for reasons that made complete sense at the time, and have simply never been revisited against the current one. The liberalisation on one side and the audit pressure on the other are, together, a reasonably clear signal about which of these structures are now sitting somewhere they would not choose to build from scratch today.
A deal of the size and visibility of the SBI deal tends to prompt exactly the kind of internal review that a routine regulatory notification may not trigger among comparable principals, watching a peer institution move confidently through a process they themselves might find difficult. The firms positioned to have a useful conversation with those principals in the weeks after a deal like this are not necessarily the ones with the deepest outbound finance practice. They are the ones with agility facilitated by their geographic partner committees, who were already tracking where the two regulatory tracks were pulling apart, and had already worked out which class of client that divergence was about to matter to, before the question arrived in their inbox rather than after.
Lawfinity Solutions advises international law firms on cross-border legal market positioning. If the India corridor is a live question for your firm, we would be interested in a conversation. Lawfinity works with one firm per jurisdiction. Engagements begin with a single conversation about your firm’s current position and where the corridor question is live for you. Write to Prachi Shrivastava
